Endocrine
Abstracts
May 2014 Volume 35
ISSN 1479-6848 (online)
16th European Congress of
Endocrinology 2014
3 –7 May 2014, Wrocław, Poland
published by
bioscientifica
Online version available at
www.endocrine-abstracts.org
Volume 35
May 2014
Endocrine Abstracts
16th European Congress of
Endocrinology
3–7 May 2014, Wrocław, Poland
EDITORS
The abstracts were marked by the Abstract Marking Panel selected by the Programme Organising Committee
ECE 2014 Programme Organising Committee
Paolo Beck-Peccoz
Anna Spada
Chair
Chair
Members
Max Bielohuby
Justo Castan˜o
Niki Karavitaki
Marta Korbonits
Krzysztof Kula
Agnes Linlart
Sten Lund
Valeriya Lyssenko
Andrej Milewicz
Efisio Puxeddu
Hans Romjin
Allan Vaag
Peter Varnai
M Donath Switzerland
J Drouin Canada
L Duntas Greece
G Eisenhofer Germany
S Farooqi UK
M Felicia Italy
A Ferlin Italy
C Follin Sweden
J Frystyk Denmark
L Fugazzola Italy
C Gaston UK
A-P Gimenez-Roqueplo France
E Gregoraszczu Poland
S Hahner Germany
N Hamdy Netherlands
T Hansen Denmark
TK Hansen Denmark
B Hemmingsen
A Hoeflich Germany
L Hofbauer Germany
P-M Holterhus Germany
E S Husebye Norway
A Januszewic Poland
N Jessen Denmark
D Jezova
A Juul Denmark
G Kahaly Germany
F Karpe UK
M Keil
F Kelestimur Turkey
RD Kineman USA
P King UK
ST Knudsen Denmark
M Korbonits UK
K Kula Poland
J Lenders Netherlands
NR Leslie UK
A Luger Austria
RM Luque Spain
M Luster Germany
M Manelli Italy
C Mathieu Belgium
J Mittag Sweden
J Newell-Price UK
M Niedziela Poland
S Nielsen Denmark
E Nieschlag Germany
P Nilsson Sweden
S Pearce UK
S Petersenn Germany
JR Petrie UK
M Pfeifer Sweden
V Pirags Latvia
A Pizzocaro Italy
D Power Portugal
PL Poulsen Denmark
M Puig Spain
S Radian UK
M Robledo Spain
C Ronchi Italy
M Rossini Italy
D Salvatore Italy
L Sa¨vendahl Sweden
N Skakkebaek Denmark
J Smit Netherlands
R Sustarsic
N Taylor UK
J Toppari Finland
M Toth
Z Toth
M Tzanela Greece
AJ Van der Lely Netherlands
J van Eck Netherlands
V Volke Estonia
J L Wemeau France
I Wilkinson UK
Z Wu Germany
P Yeoh UK
J Young France
L Zabuilene
MC Zatelli Italy
C Zillikens Netherlands
Abstract Marking Panel
A Agha Ireland
M Albiero
M Alevizaki Greece
MS Andersen Denmark
F Antoni
A Beckers Belgium
I Bernabeu Spain
J Bertherat France
F Beuschlein Germany
M Bidlingmaier Germany
M Blomberg-Jensen
Netherlands
J Bollerslev Norway
C Bousquet France
T Brue France
C Buchanan UK
F Cardona
J Castano Spain
P Chanson France
M Charalambous UK
B Chini Italy
I Chiondini Italy
L Chiovato Italy
MS Cooper Australia
L Czupryniak Poland
C Daousi UK
MT Dattani UK
W De Herder Netherlands
16th European Congress of Endocrinology 2014, Wrocław, Poland
SPONSORS
The ESE would like to thank its Corporate Members and the ECE 2014 sponsors
ECE Corporate Members
Eli Lilly
Ipsen
Laboratoire HRA Pharma
Merck Serono
Novartis Pharmacueticals
Novo Nordisk
Pfizer
Sandoz International Gmbh
ViroPharma SPRL
Gold Sponsors
Ipsen
Novartis
Bronze Sponsors
Alexion
ESE Office
Euro House
22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT, UK
ECE 2014 Secretariat
Bioscientifica Ltd
Euro House, 22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT, UK
Endocrine Abstracts (2014) Vol 35
Contact:
Tel:
Fax:
E-mail:
Web site:
Contact:
Tel:
Fax:
E-mail:
Website:
Andrea Davis
+44 (0)1454 642247
+44 (0)1454 642222
info@euro-endo.org
www.ese-hormones.org
Claire Arrigoni
+44 (0)1454 642240
+44 (0)1454 642222
conferences@bioscientifica.com
http://www.bioscientifica.com
16th European Congress of Endocrinology 2014, Wrocław, Poland
CONTENTS
16th European Congress of Endocrinology 2014
PRIZE LECTURES AND BIOGRAPHICAL NOTES
The European Journal of Endocrinology Prize Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . EJE1
The Geoffrey Harris Prize Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . GH1
PLENARY LECTURES
Genes, environment and endocrine disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Advances in molecular pathogenesis of thyroid cancer – therapeutic implications . . . . . . . . .
Good times, bad times: (patho)physiology of diurnal rhythms . . . . . . . . . . . . . . . . . . . .
Islet transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Simultaneous treatment of menopausal symptoms and prevention of breast cancer: Is it possible?
Hypothalamic inflammation - cause or consequence of obesity? . . . . . . . . . . . . . . . . . . .
Reproduction and energy metabolism, an ancestral balance to be preserved for women’s health .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
PL1
PL2
PL3
PL4
PL5
PL6
PL7
Endocrine changes and treatment needs in critically ill patients . . . . . . . . . . . . . . . . . . . .
Pituitary development – from basic research to clinical practice . . . . . . . . . . . . . . . . . . . .
News from thyroid hormones: central transport, energy control and oxidative stress . . . . . . . .
Endocrine Nurses Session 1: Craniopharyngioma . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Obesity Beyond BMI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Focus on novel developments of PCOS - conclusions from the PCOS Task Force . . . . . . . . . . .
Nontumorous pituitary diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Membrane lipid composition and receptor function. Signalling and trafficking . . . . . . . . . . . .
EYES Session - Cold metabolic inflammation in obesity: ignored complication and treatment target?
Difficulties in the treatment of Graves’ orbitopathy . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long term outcome of ‘cured’ pituitary patients . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gut microbiota in diabetes and obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Endocrine Nurse Session 3: Meet the Nurse Expert - Management of Endocrine Emergencies . . . .
Clinical outcome of medical intervention in Disorder of Sex Development (DSD) . . . . . . . . . . .
Thromboembolism and contraception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Metformin: old dog, new tricks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cushing’s syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Endocrine disease during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Osteoporosis - An update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
New hormones and endocrine tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dilemmas in hormonal replacements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Novel therapies for thyroid cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Neuroendocrine tumours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Nutrient regulation of metabolism and endocrine systems . . . . . . . . . . . . . . . . . . . . . . .
Gonadal hormones and obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pitfalls in hormone measurement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Brown Adipose Tissue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Molecular pathophysiology for clinicians: receptor-related disorders . . . . . . . . . . . . . . . . . .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. S1.1– S1.3
. S2.1– S2.3
. S3.1– S3.3
. S4.1– S4.3
. S5.1– S5.3
. S6.1– S6.3
. S7.1– S7.3
. S8.1– S8.3
. S9.1– S9.3
S10.1– S10.3
S11.1– S11.3
S12.1– S12.3
S13.1– S13.3
S14.1– S14.3
S15.1– S15.3
S16.1– S16.3
S17.1– S17.3
S18.1– S18.3
S19.1– S19.3
S20.1– S20.3
S21.1– S21.3
S22.1– S22.3
S23.1– S23.3
S24.1– S24.3
S25.1– S25.3
S26.1– S26.3
S27.1– S27.3
S28.1– S28.3
SYMPOSIA
Endocrine Abstracts (2014) Vol 35
16th European Congress of Endocrinology 2014, Wrocław, Poland
MEET THE EXPERT SESSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MTE1 –MTE17
ORAL COMMUNICATIONS
Thyroid clinical . . . . . . . . .
Adrenal Clinical . . . . . . . . .
Neuroendocrinology & Signalling
Diabetes and Obesity 1 . . . . .
Adrenal & Thyroid . . . . . . . .
Bone, Calcium & Vitamin D . . .
IGF-1 and Thyroid Basic . . . .
Pituitary Clinical . . . . . . . . .
Reproduction . . . . . . . . . . .
Endocrine Tumours . . . . . . .
Diabetes and Obesity 2 . . . . .
Pituitary Basic . . . . . . . . . .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. . OC1.1– OC1.5
. . OC2.1– OC2.5
. . OC3.1– OC3.5
. . OC4.1– OC4.5
. . OC5.1– OC5.5
. . OC6.1– OC6.5
. . OC7.1 OC7.5
. . OC8.1– OC8.5
. . OC9.1– OC9.5
OC10.1 – OC10.5
OC11.1 – OC11.5
OC12.1 – OC12.5
NURSE POSTERS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N1–N8
POSTER PRESENTATIONS
Adrenal cortex . . . . . . . . . . . . . . . . . . . .
Adrenal Medulla . . . . . . . . . . . . . . . . . . .
Bone and Osteoporosis . . . . . . . . . . . . . . .
Calcium and Vitamin D metabolism . . . . . . . .
Cardiovascular Endocrinology & Lipid Metabolism
Clinical case reports – Pituitary / Adrenal . . . .
Clinical case reports – Thyroid / Others . . . . . .
Developmental Endocrinology . . . . . . . . . . .
Diabetes (epidemiology, pathophysiology) . . . . .
Diabetes complications . . . . . . . . . . . . . . .
Diabetes therapy . . . . . . . . . . . . . . . . . . .
Endocrine disruptors . . . . . . . . . . . . . . . . .
Endocrine tumours and neoplasia . . . . . . . . .
Female reproduction . . . . . . . . . . . . . . . . .
Growth hormone IGF axis – basic . . . . . . . . .
Male reproduction . . . . . . . . . . . . . . . . . .
Neuroendocrinology . . . . . . . . . . . . . . . . .
Nuclear receptors and signal transduction . . . . .
Obesity . . . . . . . . . . . . . . . . . . . . . . . .
Paediatric endocrinology . . . . . . . . . . . . . .
Pituitary – Basic (Generously supported by IPSEN) .
Pituitary – Clinical (Generously supported by IPSEN)
Steroid metabolism and action . . . . . . . . . . .
Thyroid (non-cancer) . . . . . . . . . . . . . . . .
Thyroid cancer . . . . . . . . . . . . . . . . . . . .
INDEX OF AUTHORS
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. .
. .
. .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. . . . P1– P56
. . . P57– P64
. . P65 – P100
. P101 – P168
. P169 – P209
. P210 – P260
. P261 – P332
. P333 – P339
. P340 – P402
. P403 – P461
. P462 – P501
. P502 – P513
. P514 – P613
. P614 – P667
. P668 – P683
. P684 – P708
. P709 – P735
. P736 – P739
. P740 – P792
. P793 – P825
. P826 – P836
. P837 – P945
. P946 – P957
. P958 –P1082
P1083 –P1152
16th European Congress of Endocrinology 2014, Wrocław, Poland
Poster Presentations
Endocrine Abstracts (2014) Vol 35
16th European Congress of Endocrinology 2014, Wrocław, Poland
P955
Testosterone supplementation and sexual function: a meta-analysis
study
Giovanni Corona1, Andrea M Isidori3, Jaques Buvat4, Antonio Aversa3,
Giulia Ratrelli2, Geoff Hackett5, Vincenzo Rochira6, Andrea Lenzi3 &
Mario Maggi2
1
Endocrinology Unit, Bologna, Italy; 2Sexual Medicine and Andrology
Unit, Florence, Italy; 3Department of Experimental Medicine, Sapienza
University of Rome, Rome, Italy; 4Centre ETPARP, Lille, France; 5Good
Hope Hospital, Sutton Coldfield, UK; 6Department of Biochemical,
Metabolic and Neural Sciences, Chair of Endocrinology, University of
Modena and Reggio Emilia and Azienda USL of Modena, Modena, Italy.
Introduction
The role of testosterone supplementation (TS) as a possible treatment for male
sexual dysfunction remains questionable. The aim of the present study is to metaanalyse data evaluating the effects of TS on male sexual function and its
therapeutic synergism with the use of phosphodiesterase type 5 (PDE5i).
Methods
An extensive Medline Embase and Cochrane search was performed including the
following words: ‘testosterone’, ‘erectile dysfunction’. All randomized controlled
trials (RCTs) comparing the effect of TS vs placebo on sexual function or the
effect of TS as add on to PDE5ı` s on sexual function were included. Data
extraction was performed independently by two of the authors (A.M.I, G.C), and
conflicts resolved by the third investigator (M.M).
Results.
Out of 1702 retrieved articles, 41 were included in the study. In particular, 29
compared TS vs placebo, whereas 12 trials evaluated the effect of TS as add on to
PDE5ı`s. TS is able to significantly ameliorate erections and to improve other
aspects of male sexual response in hypogonadal patients. However, the presence
of publication bias was detected. After applying Duval and Tweedie ‘trim and fill’
method, the positive effect of TS on erectile function and libido components
retained significance only in RCTs partially or completed supported from
pharmaceutical companies (CI (0.04–0.53) and (0.12;0.52) respectively). In
addition, we also report that TS could be associated with an improvement in
PDE5i outcome. These results were not confirmed when placebo-controlled
studies were selectively analysed. The majority of them, however, included mixed
eugonadal/hypogonadal subjects.
Conclusions
TS plays positive effects on male sexual function in hypogonadal subjects. The
apparent difference between industry-supported and independent studies could
depend on trial design more than on publication bias. New RCTs exploring the
effect of TS in selected cases of PDE5i failure who persistently retain low T levels
are advisable.
DOI: 10.1530/endoabs.35.P955
of adrenal cortex as mechanism enabling a consequent synthesis of neuroprotective steroids in various human peripheral tissues. The neuroprotective effects
of individual steroids and a possible utilization of the results for the diagnosis and
treatment of MS were discussed.
DOI: 10.1530/endoabs.35.P956
P957
Role of clinical risk factors and polymorphisms in glucocorticoid
receptor gene in the determining the risk of developing new-onset
diabetes after kidney transplantation
Grazia Michetti1, Laura Trementino1, Giorgia Marcelli1, Gloria Apolloni1,
Domenica Taruscia2, Giovanni Maria Frasca2, Marco Boscaro1,
Emanuela Faloia1 & Giorgio Arnaldi1
1
Division of Endocrinology, Polytechnic University of Marche, ANCONA,
Italy; 2Nephrology and Dialysis Uinit, Polytechnic University of Marche,
ANCONA, Italy.
Introduction
New onset diabetes after transplantation (NODAT) is a recognized metabolic
complication of kidney transplantation: its rates at 12 months after transplantation
is between 20 and 50% for kidney recipients and it is associated with increased
risks of graft rejection, infection, cardiovascular disease and death. Transplantspecific risk factors for NODAT,such as corticosteroids and calcineurin
inhibitors, play a dominant role in its pathogenesis. Furthermore polymorphisms
in GR gene are common in the human population and play a role in regulation of
glucocrticoid sensitivity.
Objective
Determine the incidence genetic and clinical risk factors for NODAT among
kidney recipients in our centre.
Patients and methods
We studied 96 kidney allograft recipients without preexisting diabetes. The
presence of arterial hypertension, blood chemistry and BMI were assessed at 3, 6
and 12 months. GR gene polymorphism (BclI, A3669G) were analyzed using
RT-PCR System and Taqman allelic discrimination assays.
Results
Three months after renal transplantation 27% recipients developed NODAT.
There were no significant differences in age, mean daily steroids doses and
genetic polymorphism in GR between patients with NODAT and healthy control.
Patients with NODAT had a BMI significantly increased compared with healthy
control (25.4 vs 21.8, PZ0.02).
Conclusions
The prevalence of NODAT in our center is similar to that found in the literature.
BMI and obesity are a risk factors for NODAT. Age, daily steroids doses and
genetic polymorphism in GR are not correlates with its development.
DOI: 10.1530/endoabs.35.P957
P956
Profiling of neuroactive steroids, their precursors and metabolites in
patients suffering from multiple sclerosis
Radmila Kancheva1, Martin Hill1, Lyudmila Kancheva1, Marta Velikova1,
Miluse Pavelcova2, Luboslav Starka1 & Eva Havrdova2
1
Institute of Endocrinology, Prague, Czech Republic; 2Department of
Neurology, First Faculty of Medicine, Center of Demyellinating Diseases,
Charles University, Prague, Czech Republic.
Some steroids modulate the permeability of ionotropic receptors on cell
membranes and therefore may activate or inhibit neuronal activity depending
on the steroid structure. These neuroactive steroids (NAS) exert neuroprotective
effects like the neuronal remyelination.
Multiple sclerosis (MS) is the most common cause of neurological disability in
young adults. Therefore, the authors have followed the neuroprotective,
GABAergic, glycinergic, glutamatergic acetylcholinergic and purinergic NAS,
their precursors and metabolites and their conjugates (64 steroids)in the D4 and D5
steroidogenic pathways, estrogens, 5a/b-reduced pregnanes and androstanes
(both 17-oxo and 17b-hydroxy), 7a/b- and 16a-hydroxyderivatives of the D5
steroids, and 20a-hydroxyderivatives of the D4 and D5 steroids, and 5a/b-reduced
pregnanes in the circulation and cerebrospinal fluid of 13 female patients – 36
years old median age and 8 sex age matched healthy controls (both in the
follicular menstrual phase) with the use of gas chromatography – mass
spectrometry. The steroid conjugates were hydrolyzed and the released steroids
were detected like the case of the unconjugated ones. The primary finding was the
increased levels of C21 steroids in body fluids, which points to increased activity
Endocrine Abstracts (2014) Vol 35
Thyroid (non-cancer)
P958
A case of primary hypothyroidism: Lingual thyroid
¨ ztu¨rk1, S¸enay Arıkan2, Yunus I˙lyas Kibar1, Ahmet Tay1 &
Yasin O
Mehmet Emin Ayhan1
1
Erzurum Bo¨lge Eg˘itim ve Aras¸tırma Hastanesi ˙Ic¸ Hastalıkları, Erzurum,
Turkey; 2Erzurum Bo¨lge Eg˘itim ve Aras¸tırma Hastanesi Endokrinoloji Ve
Metabolizma Klinig˘i, Erzurum, Turkey.
Lingual thyroid is an abnormal formation appearing as the result of a deficient
descent during embryological development of the thyroid gland through the
thyroglossal duct to its normal pretracheal location, and it is a rare embryological
aberration. A 19 years old woman was admitted to with foreign-body-feeling,
dysphonia, hoarseness, constipation. Examination showed a spherical, red fleshy
and smooth contoured mass rat back of the tongue. Thyroid scan with technetium
99 m revealed isotope uptake in the base of tongue area and no uptake in the
normal thyroid location. With these findings lingual thyroid was diagnosed.
Surgical exision was not recommended since the lingual mass was the only
functioning thyroid gland and medical treatment was appropriate. We aimed to
present a case of lingual thyroid and hypothyroidism with laboratory and imaging
findings.
DOI: 10.1530/endoabs.35.P958
16th European Congress of Endocrinology 2014, Wrocław, Poland
Author Index
Abaci, N P593
Abarikwu, S P708
Abbara, A OC3.1, OC9.4
& P617
Abbaszadegan, MR P108
Abdallah, NB P840
Abdelrazek, S P1041 &
P1055
Abdin, A P320 & P552
Abdollahi, M P405
Abdulla, H P848
Abeguile, G P148
Aberer, F P488
Aberle, J P581
Abeysinghe, P P786
Abi, A P472
Abouglila, K P846
Abrahamsson, N P770
Abraitiene, A P838
Abramavicius, S P369
Abreu, A P711
Abrosimov, AY P1108
Abs, R S21.3
Acar, B P343
Acar, FZ P1036 & P31
Acibucu, F P1120
Acikgoz, E P753
Ackermans, MT P946
Adamcova, M P22
Adamek, D P829
Adamidou, F P167
& P314
Adamska, A P134 & P663
Adamska, E OC4.1 & P776
Adas, G P14
Adas, M P14
Ademoglu, E P115
Adhiyaman, V P249
Adorini, L P696
Adukauskiene, D P931
Adversi, F P643
Ae Lee, K P1085
Aflorei, ED OC12.1
Afzal, N P1032
Agackiran, Y P136
Agapito, A P654 & P780
Agata, K P124
Agbaht, K P742
Aghaei, M P71
Aghajanova, Y P120 &
P477
Aghili, R P405
Agnieszka, C OC5.5
Aguiar, A P631
Aguilar-Diosdado, M
P206, P393, P395,
P398 & P496
Ahmed, A P1089
Ahmeti, I P248
Ahn, KJ P342 & P429
Aigelsreiter, A P192
Aimaretti, G P145
AiMin, X P771
Ajduk, M P785
Akc¸ay, G P66
Akbal, E P968
Akbay, E P270 & P271
Akcay, T P821
Akgul, OF P244, P245 &
P632
Akhtar, S P951
Akin, F OC9.5, P1027,
P263, P264 & P380
Akin, S P48 & P917
Akkurt, A P531
Akopyan, S P120
Akpinar, G P1010
Akpinar, S P275
Aksana, K P805
Aksoy, A P115
Aksyonova, E P778
Aktimur, R P126
Akturk, M P1030, P151,
P492 & P700
Akyildiz, M P171 & P172
Al-Dujaili, E P170
Al-Hayek, A P351
Al-Sabaan, F P351
Al-Saeed, A P351
Alacacioglu, A P332
Albarel, F P875
Alberiche, MdP P1073
Albersmeyer, M P868
Alborg, VC P909
Albrecht, E P739
Alebic, MS P686
Aled Rees, D OC5.2
Aleksandra, K OC5.5
Alesse, E P834 & P835
Alevizaki, M P1080 &
P1102
Alexander Iwen, K OC7.5
Alexandraki, K P537,
P598 & P608
Alexianu, M P815
Alexopoulou, O P860
Alfaro, JJ P467
Algu¨n, E P10
Alhumaidi, N P77
Ali Alhamza, AH P1
Ali Mansour, A P1
Ali, LA P542
Aliev, A P1050 & P584
Alikasifoglu, M P388
Alimova, N P358 & P417
Alkhalaf, F P77
Allelein, S P613
Allolio, B OC2.2, OC3.2,
OC5.3, P2, P533 &
P535
Almagro, RM P1002 &
P1003
Almanza, MR P909
Almeida, R P823, P926 &
P943
Almeida, T P654
Almomin, AMS P1
Alobedallah, A P351
Alonso, AA P575
Aloumanis, K P67 & P68
Alt-Tebacher, M P1042
Altas, A P1058
Altieri, B P535
Altinok, M P618
Altinova, A P446 & P492
Altinova, AE P1030 &
P151
Altun, B P968
Altunbas, HA P131, P74 &
P900
Altundal, N P894
Altunel, MS P432 & P433
Altunkaya, C P279 &
P285
Altunoren, O P238
Altuntas, Y P221 & P472
Alves, M P1009, P327,
P53, P546 & P547
Alves, MG P571
Alves, MR P702
Alves, R P461
Amani, MEA P984 & P985
Amar, L P49
Amaral, C P329, P457,
P764 & P769
Amaral, D P807
Amaral, FG P719
Amaro, T P1149
Ambroziak, U P338
Ammini, A P335
Ammini, AC P580 & P582
Amrani-Raissouni, T P106
Amselem, S P675
Amzar, D P543, P573 &
P893
Anaforog˘lu, P10, P23 &
P729
Anagnostis, P P167 &
P314
Anastasiu, D P65
Andersen, AS P337
Andersen, LLT P621
Andersen, M P618, P621
& P673
Andersen, MN OC1.2
Anderwald, C P129
Andrada, P P781
Andreas, B P714
Andreas, H P714
Andres, E P1042
Androulakis, I P641
Andrusiewicz, M P1119 &
P836
Andrysiak-Mamos, E
P100, P604 & P99
Andujar-Plata, P P731
Anelli, S P530
Angelini, F P937
Angelini, M S16.3
Angelopoulou, A P1102
Angelova, P P156
Anghel, GC P733
Anghel, R P734
Anheˆ, GF P719
Anil, C P403 & P468
Anna, S P180
Ansaloni, A P1053 &
P924
Ansari, NE P72
Antic, IB P299, P313,
P623, P624 & P625
Antic, S P828
Antiguedad, CG P445
Anton, M P814
Antonelou, M P920
Antosz, A P587
Antunes, A P823
Anwer, U P685 & P699
Aout, M P885 & P907
Apaydin, MA P863
Apollonatou, S P950
Apolloni, G P957
Apostolakis, M P1102
Arıkan, P958
Arau´jo-Vilar, D P811
Arabaci, E OC1.1
Aragu¨e´s, JM P350
Arakelyan, L P120
Aral, F P593
Aral, Y P385
16th European Congress of Endocrinology 2014, Wrocław, Poland
Regadera, J P738
Reghina, AD P431
Reimondo, G P8
Reincke, M MTE5, OC2.2,
OC5.4, P203, P37,
P564, P568 & P7
Reisch, N S14.1
Renata, C P1103
Rentziou, G P1102
Requena, JR P811
Requena, M P237 & P445
Rese´ndiz, KH P918
Resch, J OC7.5
Resmini, E OC12.5
Ress, C P861
Reyes-Garcı´a, R P91
Rezvani, R P773
Rheinheimer, J P365
Ribalta, MT P722
Ribeiro, C P1111
Riesco-Eizaguirre, G PL2
Ricciuti, A OC12.3
Richard, N P148
Richter-Unruh, A S14.1
Ricotti, R P145 & P27
Ridruejo, E P687
Ries, M P2
Rieske, P P97 & P98
Riester, A P37 & P568
Rigas, G P748
Rimpau, J P735
Rinaldi, E P47
Rinco´n-Ferna´ndez, D
P516
Rindi, G P549, P551 &
P578
Ripoll, RQ P909
Risbridger, G OC10.4
Ritvonen, E P881
Ritzel, K P7
Rivadeneira, L P237 &
P445
Rivera, NG P51 & P597
Rivera, R P741
Rivero-Corte´s, E OC12.2
Rivory, P P652
Rizoulis, A P1054
Rizvi, S P1031
Rizvi, SSR P1032, P685 &
P699
Roa, R P487
Roberts, J P914
Robledo, M P1095
Roca, M P500
Roca-Rodrı´guez, M P261
Roccio, M P27
Rochira, V P1053, P519,
P701, P924 & P955
Rodrı´guez Gutie´rrez, FJ
P1003
Rodrı´guez, C P1073
Rodrı´guez, E P1073
Rodrı´guez, JP P51 & P597
Rodrı´guez, R P322
Rodrı´guez-Medina, B
P695
Rodrı´guez-Molina, JM
P186
Rodrigues, D P1009,
P296, P325 & P327
Rodrigues, E P889
Rodrigues, P P17
Rodrigues, SC P719
Rodriguez, JP P498
Roemmler-Zehrer, J P735
Rogin´ska, D P54
Rogowicz-Frontczak, A
P378 & P420
Roine, R P881
Rojo-Martinez, G P789
Roma´n, MM P376
Romanelli, MMC P766
Romero, AO P743
Romero, MF P743
Romualdi, D P653
Ronchi, C OC2.3 & P533
Ronchi, CL OC2.2, OC5.3
& P535
Rosłonowska, E P557
Rosado, V P1095
Rosc, D P408
Rosca, R P204
Rosca, RI P529
Rosell, J P515
Rosenwald, A OC5.3
Roskosz, J OC1.5
& P1098
Roslon, M P1139
Ross, I P40
Ross, R P30 & P825
Ross, RJ OC5.2
Rossetti, P P1007
Rossetti, R P646
Rossi, M P692, P694 &
P704
Rossi, S P1126
Rostomyan, L P834
Roszak, M P1021
Rotermund, R P581
Rothenbuhler, A P140
Rotondi, S P834 & P835
Rousso, D P1047
Roux, A P652
Rozhinskaya, L P119, P24,
P730, P912, P919 &
P934
Rozhko, A P181
Rozkowszka, K P557
Ruas, L P1008, P1009,
P1111 & P296
Rubin, B P12 & P536
Rubino, M P128
Ruby, LCH P771
Ruchała, M P1035,
P1044, P1119, P202,
P338, P36, P836,
P982 & P983
Ruchala, M P326, P563,
P996 & S10.2
Rudnicka, M P99
Rudnik, A P832
Rudzinska, M P1131 &
P1135
Rudzki, G P254, P258 &
P556
Ruiz-Riquelme, A P811
Rupa, R P849
Ruprecht, Z P408
Rusak, M P776 & P818
Rusakov, V P266, P267
& P268
Rusalenko, M P181
Rusinek, D OC3.5 & P1152
Rusu, C P795, P814
& P819
Ruszkowska-Ciastek, B
P408
Ruszniewski, P P577
& P578
Rutishauser, J OC3.2
& P18
Rutkowska, A P511
Rutkowska, B P952
Rutter, M OC11.2
Ruvo, MD P831
Rybalchenko, V P422
Rybka, J P372
Rybka, W P372
Rydzanicz, M P338
Rymaszewska, J P127
& P930
Rys, A P157, P309 &
P777
Ryu, OH P384
Ryzhenkova, MI P1108
Sa´, J P389 & P390
Sa´daba, MC P669
Sa´nchez, A P1073
Sa´nchez, F P205
Sa´nchez, JRC P575
Sa´nchez, R P1073
Sa´nchez-Garcı´a, F P515
Sa´nchez-Iglesias, S P811
Sa´nchez-Zambrano, M
P205
Sa´sikova´, M P884
Se˛siadek, M P890
Słapa, R P557
Słoka, N P127
Słowin´ska-Srzednicka, J
P557
Sørensen, H P673
Sørensen, JA P621
Saad, F P478, P696, P754
& P755
Saaid, N P107
Saavedra, A P936
Sabino, T P654 & P780
Sabir, I P335
Sabt, A P77
Sacchi, S P639
Sacikara, M P136, P305,
P635, P980 & P987
Sadikova, E P142 & P375
Sadowski, T P160
Sadurska, E P1004
Sadykova, A P417 & P418
Saeger, W P901
Safari, R P71
Sag, S P753
Sagala, M P806
Saglam, F P1065, P305,
P421, P78 & P981
Sagliker, HS P231 & P301
Sahin, D P442
Sahin, F P69
Sahin, H P244 & P295
Sahin, I P1048 & P490
Sahin, M OC8.3, P139,
P146, P183, P228,
P230, P231, P238,
P244, P245, P295,
P301, P437, P5, P632,
P638 & P994
Saini, S P746
Saito, H P76
Sajardo, RB P575
Sajevets, T P277
Sajid, W P337
Sak, SD P61
Sakamoto, M P232 &
P897
Sakamoto, N P232
Saklamaz, A P171 & P172
Sala, E P845 & P898
Sala, GBL P643
Salam, R P107 & P959
Salas, MS P237 & P445
Salas-Salvado´, J S29.1
Salcuni, AS P81
Salgado, C P1149

papirus kağıt stok durumu

Endocrine Abstracts vol 35